Barry J. Simon - 22 Jan 2025 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Director
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol: IBRX
Transactions as of: 22 Jan 2025
Net transactions value: +$219,864
Form type: 4
Filing time: 24 Jan 2025, 20:47:52 UTC
Previous filing: 24 Jun 2024
Next filing: 25 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IBRX	Common Stock	Options Exercise	$219,864	+110,020	+3.5%	$2.00	3,233,781	22 Jan 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Stock Option (right to buy)	Options Exercise	$0	-110,020	-100%	$0.000000	0	22 Jan 2025	Common Stock	110,020	$2.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Cash exercise of options scheduled to expire on February 16, 2025.
F2	Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option was January 16, 2015.